Literature DB >> 9302376

Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma.

P F Collet-Solberg1, H Sernyak, M Satin-Smith, L L Katz, L Sutton, P Molloy, T Moshang.   

Abstract

OBJECTIVE: We have evaluated the frequency of endocrine abnormalities in a large group of patients with hypothalamic/chiasmatic glioma (H/CG) and its correlation with the different forms of therapy.
DESIGN: Descriptive retrospective study using case note review analysis. PATIENTS: The records of 68 children who survived H/CG were analysed. One third had neurofibromatosis. The mean age at tumour presentation was 5 years. The median time of follow-up was 3.6 years. Thirty-eight children received cranial radiation, of whom 17 also had surgery. Surgery was performed in a total of 24 patients. Fifteen patients received only chemotherapy. Eight children, all with neurofibromatosis, received no specific tumour treatment. MEASUREMENTS: Endocrine dysfunction was determined by clinical manifestations and biochemical evaluation of hypothalamic-pituitary function.
RESULTS: Endocrine dysfunction occurred in 42% of the children. The most common disorder was GH deficiency (GHD). Of 50 children evaluated, 15 of the 19 with GHD received cranial irradiation (P < 0.05). HOwever, 15 children treated with more than 15 Gy grew normally. Precocious puberty was diagnosed in 11 patients. Nine patients, all treated with cranial irradiation, developed hypogonadotrophic hypogonadism. Of the 14 patients with hypothyroidism, 10 had surgery (P < 0.005). Hypoadrenalism and diabetes insipidus each occurred in eight patients, and were associated with multiple endocrine deficiencies and surgery. Endocrine deficiencies occurred in children with neurofibromatosis as frequently as children without neurofibromatosis but only when comparing those treated with cranial irradiation or surgery.
CONCLUSIONS: Nearly all studies assessing the patients with different tumour therapy evaluate patients wit different tumour types. This study investigates a specific and large population of patients with H/CG and correlates the different form of treatment with the endocrine outcome. Precocious puberty, in children with this tumour, is probably due to tumour location rather than oncological therapy. Conversely, although endocrine deficiencies can be a result of tumour location, the major causes of endocrine abnormalities were field irradiation and tumour surgery. A notable finding not previously reported is that endocrine dysfunction occurs less often in neurofibromatosis patients treated conservatively. Furthermore, this study documents that a significant number of young children grew normally despite receiving brain irradiation of greater than 45 Gy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302376     DOI: 10.1046/j.1365-2265.1997.2211032.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?

Authors:  Kristian Aquilina; David J Daniels; Helen Spoudeas; Kim Phipps; Hoong-Wei Gan; Frederick A Boop
Journal:  Childs Nerv Syst       Date:  2015-08-16       Impact factor: 1.475

3.  Optic pathway glioma: outcome and prognostic factors in a surgical series.

Authors:  Yong Ahn; Byung-Kyu Cho; Seung-Ki Kim; You-Nam Chung; Chang Sub Lee; Il Han Kim; Sei Won Yang; Hee-Soo Kim; Hyun Jib Kim; Hee-Won Jung; Kyu-Chang Wang
Journal:  Childs Nerv Syst       Date:  2006-04-21       Impact factor: 1.475

4.  Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003.

Authors:  Martin Benesch; Herwig Lackner; Petra Sovinz; Elisabeth Suppan; Wolfgang Schwinger; Hans-Georg Eder; Hans Jürgen Dornbusch; Andrea Moser; Karin Triebl-Roth; Christian Urban
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

5.  Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy.

Authors:  Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

Review 6.  MRI of the hypothalamic-pituitary axis in children.

Authors:  Maria I Argyropoulou; Dimitrios Nikiforos Kiortsis
Journal:  Pediatr Radiol       Date:  2005-06-01

7.  Optic pathway gliomas in adolescence--time to challenge treatment choices?

Authors:  Amy Lee Chong; Jason D Pole; Katrin Scheinemann; Juliette Hukin; Uri Tabori; Annie Huang; Eric Bouffet; Ute Bartels
Journal:  Neuro Oncol       Date:  2013-01-07       Impact factor: 12.300

8.  Survival and long-term health and cognitive outcomes after low-grade glioma.

Authors:  Gregory T Armstrong; Heather M Conklin; Sujuan Huang; Deokumar Srivastava; Robert Sanford; David W Ellison; Thomas E Merchant; Melissa M Hudson; Mary Ellen Hoehn; Leslie L Robison; Amar Gajjar; E Brannon Morris
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

9.  Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children.

Authors:  E Osztie; P Várallyay; N D Doolittle; C Lacy; G Jones; H S Nickolson; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

10.  Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.

Authors:  Weizhen Xu; Anna Janss; Roger J Packer; Peter Phillips; Joel Goldwein; Thomas Moshang
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.